Avanzanite Bioscience

Amsterdam, The Netherlands

Avanzanite Bioscience enhances access to orphan drugs in Europe, partnering with pharma for rare disease treatments.

$37.1M raised

Nov 2025

Series A

Advice Health Care Pharmaceutical

Top Investors

MVM Life Science Partners

Founder Contacts

19,000+ verified contacts

Get Instant Access

Emails, phones & LinkedIn profiles

Frequently Asked Questions about Avanzanite Bioscience

How much funding has Avanzanite Bioscience raised?

Avanzanite Bioscience has raised $37.1M in total funding. The most recent round was Series A. The last funding was announced in November 2025.

Who are Avanzanite Bioscience's investors?

Avanzanite Bioscience's investors include MVM Life Science Partners.

Where is Avanzanite Bioscience headquartered?

Avanzanite Bioscience is headquartered in Amsterdam, The Netherlands.

What does Avanzanite Bioscience do?

Avanzanite Bioscience enhances access to orphan drugs in Europe, partnering with pharma for rare disease treatments.

What stage is Avanzanite Bioscience at?

Avanzanite Bioscience is at the Series A stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated November 18, 2025.

MLA

"Avanzanite Bioscience — Funding & Investors." VCBacked, November 18, 2025, https://www.vcbacked.co/company/avanzanite-bioscience. Accessed June 17, 2026.

APA

VCBacked. (2025). Avanzanite Bioscience — Funding & Investors. Retrieved June 17, 2026, from https://www.vcbacked.co/company/avanzanite-bioscience

Wikipedia (cite web)

{{cite web |title=Avanzanite Bioscience — Funding & Investors |url=https://www.vcbacked.co/company/avanzanite-bioscience |website=VCBacked |access-date=June 17, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated November 18, 2025.